Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 + pembrolizumab ± bevacizumab in recurrent/metastatic cervical and endometrial cancer
NCT07054567Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2025
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in Cervical Cancer (CC), endometrial cancer (EC), sponsored by Biokin Pharmaceutical. Started Aug 2025; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07054567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07054567.